Advances in drug resistance mechanism of immunologic checkpoint blockers and related reveral treatment

Yehui Shi, Zhongsheng Tong

    Research output: Contribution to journalArticle


    Immunotherapy is another breakthrough anti-tumor therapy, following traditional radiotherapy, chemotherapy, and targeted therapies. Immune checkpoint blockers (ICBs) have shown remarkable effects in the treatment of many malignant tumors. Given the prevalent application, ICB resistance is currently one of the most important issues in immunotherapy. This review discusses the possible mechanisms of ICB resistance, as well as methods for reversing ICB resistance, mainly through drug combinations, including combinations of radiation therapy, chemotherapy, targeted therapy, and other ICBs.

    Original languageEnglish (US)
    Pages (from-to)812-815
    Number of pages4
    JournalChinese Journal of Clinical Oncology
    Issue number15
    StatePublished - Jan 1 2018



    • Combination therapy
    • Drug resistance
    • Immune checkpoint blockers
    • Immunotherapy

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this